To begin to address this, we treated conventional GBM cell lines with either the SFK inhibitor PP2 or dasatinib (BMS-354825; Sprycel®), a clinically-relevant ATP competitive multi-targeted kinase inhibitor that inhibits all SFK members, including Src, Lyn, Fyn and Yes [18], [21]. This evidence concerns the gene FYN and glioblastoma.